SNDX insider buying and SEC filings, explained
Syndax Pharmaceuticals Inc · CIK 1395937
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$781K
Planned sales (10b5-1)
$2.1M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 29, 2026 | Planned (10b5-1) | Dennis Podlesak (Director) sold 8,000 shares at $14.21 ($114K), marked as a 10b5-1 plan trade. Holdings down 3% to 239,763 shares. | SEC filing Filed Oct 30, 2026, 7:09 PM ET |
| Jul 8, 2026 | Planned (10b5-1) | Michael A Metzger (CEO and Director) sold 32,375 shares at $24.24 ($785K), marked as a 10b5-1 plan trade. Holdings down 6% to 484,843 shares. | SEC filing Filed Jul 9, 2026 |
| Jun 11–12, 2026 | Planned (10b5-1) | Nicholas A.J. Botwood (Head of R&D, CMO) sold 65,515 shares between Jun 11 and Jun 12 at about $18.07 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 52% to 60,885 shares. | SEC filing Filed Jun 12, 2026 |
| Jun 1, 2026 | Sale | Keith A. Goldan (CFO) sold 1,177 shares at $18.99 ($22K). Holdings down 1% to 139,252 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 2, 2026 |
| Jun 1, 2026 | Sale | Michael A Metzger (CEO and Director) sold 6,847 shares at $18.99 ($130K). Holdings down 1% to 484,843 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 2, 2026 |
| Feb 9, 2026 | Sale | Michael A Metzger (CEO and Director) sold 17,159 shares at $21.03 ($361K). Holdings down 3% to 491,690 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 10, 2026 |
| Feb 9, 2026 | Sale | Keith A. Goldan (CFO) sold 3,410 shares at $21.03 ($72K). Holdings down 2% to 140,429 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 10, 2026 |
| Feb 6, 2026 | Sale | Michael A Metzger (CEO and Director) sold 7,412 shares at $20.62 ($153K). Holdings down 1% to 508,849 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 6, 2026 |
| Feb 6, 2026 | Sale | Keith A. Goldan (CFO) sold 2,082 shares at $20.62 ($43K). Holdings down 1% to 143,839 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 6, 2026 |
13 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
| Tag | Items | Filed | Source |
|---|---|---|---|
| CFO departure Detected from the filing text | 8-K Item 5.02 | Nov 2, 2026, 4:02 PM ET | SEC filing |
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 2, 2026, 4:02 PM ET 8-K | Earnings released (Item 2.02) Executive or director change (Item 5.02) | CFO departure Detected from the filing text | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SNDX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.